Tenderwize
Zurück zur Suche

Open House Originale Contract for Sofosbuvir/Velpatasvir/Voxilaprevir

Techniker Krankenkasse·Hamburg, Germany·Deadline Aug 30, 2027 · 371 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-21 - Sofosbuvir, Velpatasvir, Voxilaprevir (Wirkstoffkombination)

62/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

62 / 100

Komplexität

58 / 100

Risikofaktoren

Offers/contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature...

Only pharmaceutical undertakings for the relevant medicines, with the required seat and marketing authorisation, may pa...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Supply/rebate contract for pharmaceutical products concerning the combination Sofosbuvir, Velpatasvir, Voxilaprevir.
  • Nationwide performance in Germany.
Vollständige Zusammenfassung anzeigen

Open House-style pharmaceutical supply arrangement by Techniker Krankenkasse for the fixed combination Sofosbuvir/Velpatasvir/Voxilaprevir. The notice states there is no exclusivity, no individual negotiation, and contracts can be joined at any time during the term. The contract term runs from 2025-09-01 to 2027-08-31 at the latest, with earlier automatic end if patent/market exclusivity expires. No contract value is stated. Participation is restricted to pharmaceutical companies meeting the stated legal and self-declaration requirements, and submission is not via the portal but by email or post.

Risiken

Offers/contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature...

Only pharmaceutical undertakings for the relevant medicines, with the required seat and marketing authorisation, may pa...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of § 4 Abs. 18 AMG for the relevant medicines.
  • Applicant must have its seat in Germany, another EU Member State, or another EEA State.
  • Applicant must hold a valid marketing authorisation for the relevant medicines or otherwise be entitled to place them on the market in its own name.

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Open House Originale Contract for Sofosbuvir/Velpatasvir/Voxilaprevir

Single lot covering rebate contracts for the medicinal product combination Sofosbuvir, Velpatasvir, Voxilaprevir. Scope is nationwide in Germany. The notice says the arrangement is open to all suitable pharmaceutical companies, with uniform conditions, no exclusivity, and no individual negotiations. The lot information comes from structured data and the XML notice.

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

Aug 2025 - Aug 2027

Kategorie

Pharmaceutical products

Frist

Deadline Aug 30, 2027

Vergabedetails

Veröffentlichungsdatum
22 Jul 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
481017-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3